Study Investigating the Safety, Tolerability, PK and Food Effect of BEN8744.
Summary
BEN8744 is an experimental new medicine for treating inflammatory bowel diseases such as Ulcerative Colitis. The study will test single and repeated oral doses of BEN8744 or placebo. BEN8744 is a first in human study, so will start with a small dose and the dose will be increased as the study progresses. The goal is to find out its side effects and blood levels when taken by mouth and whether food affects the blood levels. This is a 3-part study (Parts A, B and C) in up to 108 healthy people, aged 18-65. Part A, will include up to 64 participants, single doses of BEN8744 or placebo. They'll take about 2 weeks to finish the study, stay on the ward for 4 nights and 5 days in a row and make 2 outpatient visits. Part B, will include up to 12 participants, single doses of BEN8744 with and without food. They'll take up to 3 weeks to finish the study, stay on the ward for 4 nights and 5 days in a row on 2 occasions, and make 2 outpatient visits. Part C will include up to 32 participants repeat doses of the BEN8744 or placebo for 14 days. They'll take about 4 weeks to complete the study, stay on the ward for 17 nights and 18 days in a row and make 2 outpatient visits.
Timeline
- Start
- 2023-08-30
- Primary completion
- 2024-03-14
- Completion
- 2024-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEN8744 | Unknown | 2 mg | Oral |
| Subject | BEN8744 | Unknown | 6 mg | Oral |
| Subject | BEN8744 | Unknown | 20 mg | Oral |
| Subject | BEN8744 | Unknown | 30 mg | Oral |
| Subject | BEN8744 | Unknown | 50 mg | Oral |
| Subject | BEN8744 | Unknown | 60 mg | Oral |
| Subject | BEN8744 | Unknown | 100 mg | Oral |
| Subject | BEN8744 | Unknown | 120 mg | Oral |
Indications
No indication recorded.